CareFusion Corp.

裁员仍在持续。 据药研网统计，10月宣布减员的药企数量仍高达20家，比去年增长25%。 其中，拜耳、强生和辉瑞等大型生物药企裁员近 500 名员工，裁员主要原因为管线调整及资源的重新分配。 2024年10月裁员汇总 拜耳、强生和辉瑞将裁员近 500 名员工 本月，三家大型MNC总计裁员近500人，拜耳和强生公司正在裁员他们的新泽西总部的员工，辉瑞公司正在裁员爱尔兰的制造业工作岗位。 辉瑞按照2027年底削减15亿美元成本的计划，爱尔兰将裁减多达 210 个制造业工作岗位。辉瑞裁员5次！其首席科学官、肿瘤部门商业总裁将离职 拜耳按照“新的运营模式”，将于12月27日在其新泽西州惠帕尼总部裁员57名员工。拜耳：半年四次裁员，高管离职 强生由于业务需求而发生的组织变化,将在新泽西州的新布朗瑞克总部裁员231名员工，自12月27日起生效。 辉瑞本月连续3批裁员 除了10月初辉瑞公布按降本计划的爱尔兰制造岗削减行动外，10月23日，辉瑞在其位于美国堪萨斯州麦克弗森的工厂发出了 80 份裁员通知，该通知主要影响管理和工程职位；此外由于III 期杜氏肌营养不良症（DMD）失败，辉瑞再次裁员桑福德工厂 75 人。 药明康德拟出售部分海外资产 据英国《金融时报》报道，药明康德寻求出售其位于费城的四家工厂的细胞和基因疗法先进疗法生产部门（ATU）。同时，药明生物已经聘请了顾问来帮助评估买家对其欧洲部分生产基地的兴趣。10月8日，药明康德发布自愿性公告回应了关于出售WuXi ATU业务传闻，称：出售资产的考虑与《生物安全法案》没有关系，只是例行评估，尚无定论。公司正在评估继续运营相关业务的选项，以满足员工和患者的需求。通常情况下，企业业务重组、出售或关闭将可能涉及到裁员。 安斯泰来基因疗法子公司职位变动 据Fierce Pharma报道，在以1.02亿美元收购西雅图的Universal Cells 6年后，安斯泰来制药将在日本筑波的研究园区开设第二个地点Universal新址，从西雅图Universal公司转移12个职位至日本园区，同时裁撤西雅图西雅图Universal 24个职位。关于角色变动和新站点，安斯泰来表示此举将增强 Universal Cells的基因编辑能力，并将其发展成为细胞疗法研发的卓越中心。 Turnstone Biologics 战略重组，将裁员约60% 10月11日，据悉，Turnstone Biologics进行战略重组，将裁员约60%（约48人），更换领导团队，将资源集中在肿瘤浸润淋巴细胞（TIL）疗法，预计将将其现金跑道延长至2026 年Q2。 两家医疗设备公司大幅度裁员 据WARN, 医疗技术公司美敦力（Medtronic）将于12月4日在其位于加利福尼亚州圣安娜的工厂裁员237名员工。其开发的技术包括心脏设备和患者监护系统。 此外，全球医疗技术公司 Becton， Dickinson and Company 的全资子公司CareFusion Resources于9月10日在圣地亚哥的两个地点解雇了183 名员工。CareFusion开发的技术包括输液泵、自动配药和患者识别系统。   赢创Evonik再次裁员高达260人 近日，特种化学品集团赢创Evonik正在重组涂料和粘合剂树脂以及医疗保健两条业务线，未来将重点发展核心专业领域，包括复杂且高效的API、口服和注射给药，以及精准生物解决方案。这涉及到业务重组、出售或关闭及因此可能带来的裁员问题。 继此前其裁员多达2,000名员工的消息后，赢创于10月11日再次宣布，由于德国哈瑙停止生产酮酸，到 2025 年底将裁员约 260 人。另据赢创表示，虽然法国哈姆和中国武鸣地区工厂和德国哈瑙业务相同，但考虑到这两个市场的酮类和药用氨基酸业务潜力巨大，赢创不考虑关闭这些工厂，而是考虑合资或出售等方式。  武田终止亨廷顿病项目并裁员 10月15日，据Wave Life Sciences提交给美国证券交易委员会（SEC）的一份文件中表示，武田已选择终止其在Wave的WVE-003临床阶段亨廷顿病项目，将在马萨诸塞州两个地点裁员79人。WVE-003是一款等位基因选择性反义寡核苷酸（ASO），至此两家公司之间的长期协议已“立即到期”。 Sage Therapeutics停止AD候选药物开发  Sage Therapeutics在研的NMDA 受体正向变构调节剂Dalzanemdor治疗帕金森病性痴呆的 II 期 PRECEDENT 研究、治疗AD的 II 期 LIGHTWAVE 研究相继失败。在其宣布停止开发治疗AD的 dalzanemdor后，该公司将进行战略重组，在年底裁员大约55%研发人员（超 165 人），重组最高管理层。 据 Sage 称，此次重组旨在支持 Zurzuvae 在产后抑郁症中的持续上市。Dalzanemdor目前仅剩下亨廷顿舞蹈病的III期临床在研，公司预计今年晚些时候公布亨廷顿舞蹈病的 II 期 DIMENSION 研究结果。 End 声明：本公众号所有发文章(包括原创及转载文章)系出于传递更多信息之目的，且注明来源和作者。本公众号欢迎分享朋友圈或大群，谢绝媒体或机构未经授权以任何形式转载至其他平台。 转载/商务/投稿 | 联系微信15618157102（sum_Gmi） 商务合作 稿件征集 点击了解详情 往期回顾 1 8月 | 高达22家药企裁员 2 国产首款四价HPV疫苗拟纳入优先审评 3 3. 7亿美元!今年规模最大的生物医药融资诞生

NEWS RELEASE: Avania Appoints Recognized CRO and MedTech Industry Leader, Jason Monteleone, as New President and CEO BILTHOVEN, Netherlands; BOSTON – Avania — the leading global MedTech clinical research organization (CRO) providing product development, market access, and clinical contract research services — announces the appointment of Jason Monteleone as president and CEO, effective September 2, 2024. Monteleone succeeds Sapna Hornyak, who had served as president and CEO since 2019. Under Hornyak’s leadership, Avania developed a strong, integrated global MedTech platform, which Jason will further enhance through growth initiatives, deeper therapeutic specialization, and innovation to solidify Avania’s position as a leading MedTech CRO. With over 25 years of experience in the CRO, medical device, and life sciences sectors, Monteleone brings deep expertise in driving growth, innovation, and operational excellence. From 2017 until 2021, Monteleone was CEO of Clinipace, a global midsize CRO, where revenue increased 65% under his tenure before being acquired by dMed in April 2021. While chief financial officer at Theorem Clinical Research, a global midsize CRO focused on pharmaceutical and medical device studies, revenue and head count doubled before being acquired by Chiltern International in September 2015. Most recently, Monteleone served as president of Ancillare, a global provider of ancillary supplies and equipment for clinical trials. Additionally, Monteleone is a board member and audit chair for the Drug Information Association (DIA), the leading global multidisciplinary life science membership association driving collaboration in drug, device, and diagnostic development in pursuit of a healthier world. Monteleone founded Pivotal Financial Consulting, advising investors and companies in clinical research on acquisitions, growth strategies, and innovation. He was also director of finance at VIASYS Healthcare, a publicly traded medical device company, before its acquisition by Cardinal Health and merger into CareFusion. “I am honored to join Avania and lead this exceptional team at such an exciting time in our industry,” said Monteleone. “Avania partners with some of the world’s most innovative companies in numerous therapeutic areas such as cardiovascular, neurology, orthopedics, and aesthetics to name a few. The privilege to assist our customers in developing life-changing products for patients is the reason we are passionate about what we do, driving us to innovate, collaborate, and deliver excellence in every project.” Todd Pope, chairman of Avania’s board, added, “I look forward to working closely with Jason as he leads Avania to continue making a positive impact for our customers, employees, and the MedTech community. The executive team and board are excited about the future as we bring Avania to the forefront of innovation and operational excellence.” Edouard Pillot, partner and co-head of Astorg Mid-Cap, the majority shareholder in Avania, remarked, “We are excited to welcome Jason as Avania’s new CEO. His exceptional track record of driving growth and operational excellence, combined with his experience in scaling businesses, make him the perfect leader for Avania’s next phase. With deep expertise in the CRO and MedTech industries, Jason will drive innovation and deliver distinctive solutions for our customers. We look forward to seeing Avania create long-term value for its stakeholders under his leadership.” About Avania Avania is a leading, global full-service contract research organization focused on the management of clinical studies for medical devices, IVDs, biologics, and device-drug combination products internationally. Avania supports products from the first-in-human phase through the post-market phase with the same customized approach. When you need to advance your medical technology, it takes Avania. Avania’s vision is to be your trusted global partner in the evolution of your medical technology from innovation to commercialization to improving patient health and well-being. The opinions expressed in this news release are the author’s only and do not necessarily reflect those of Medical Design & Outsourcing or its employees.

New Appointments Underscore Commitment to Driving Innovation and Industry-Leading Growth LAKE FOREST, Calif.--(BUSINESS WIRE)-- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced Nancy Sabin has been named Chief Marketing Officer and Nathaniel Sisitsky has been named General Counsel. Both will serve on the Company’s executive committee and report to Tom Frinzi, STAAR Surgical’s President and CEO. This press release features multimedia. View the full release here: Nancy Sabin, Chief Marketing Officer, STAAR Surgical (Photo: Business Wire) “We are thrilled to strengthen the STAAR team with the addition of Nancy and Nate, two seasoned executives with extensive senior leadership experience. They will play an integral role in accelerating our momentum and thereby growing the market for our surgeon customers who provide patients visual freedom from contact lenses and glasses with our lens-based technology,” said Tom Frinzi, President and CEO of STAAR Surgical. “Nancy is a perfect fit for the newly created Chief Marketing Officer position and will be critical to driving our brand awareness and innovation globally. She is a proven commercial leader with an extensive track record of delivering growth within consumer products, OTC pharmaceuticals and medical devices during her 20-year career with various franchises at Johnson & Johnson. Nate takes on an important role as our new General Counsel overseeing our legal functions globally. Nate brings to STAAR extensive experience providing legal advice and counsel to public companies, including 15 years in med-tech. He joins us from NuVasive where he was instrumental in its successful $3 billion merger with Globus Medical.” Frinzi continued, “I would like to express my utmost gratitude to Sam Gesten, STAAR’s former general counsel, who retired after 12 years of service earlier this year. We are grateful for his tireless work in moving the company forward and wish him all the very best in the future.” Nancy Sabin joined the team from Johnson & Johnson (J&J) where she most recently served as VP of Marketing and Connected Commerce for J&J Vision managing based marketing, digital strategy and connected commerce functions for the ACUVUE™ contact lens business in the U.S., one of J&J’s businesses with annual sales of at least $1 billion. Prior, she led Global Marketing for J&J Vision on the surgical side, driving innovation and equity for its industry leading global intraocular lenses. She has also held marketing leadership roles across J&J Consumer and J&J MedTech; with responsibility for driving growth and building global brands like TYLENOL™; ZYRTEC™ and ETHICON™. Nancy holds an M.B.A. from the University of Pennsylvania’s Wharton School of Business and a B.S. in Engineering from Duke University. Ms. Sabin stated, “I am delighted to be a part of STAAR during this critical phase in the company's growth. I am a huge believer in the transformation made possible thanks to our EVO ICLs and look forward to elevating the STAAR and EVO brands among surgeons and their patients. I am excited and honored to lead our marketing teams worldwide.” Nathaniel Sisitsky joined STAAR Surgical from NuVasive, Inc., a medical device company, where he served as Senior Vice President, General Counsel and Corporate Secretary since 2018. Prior to joining NuVasive, he served as Vice President and Associate General Counsel at CareFusion Corporation, a global medical technology company, and as Vice President, Legal – Corporate Finance at American Tower Corporation, a global owner and operator of wireless communication sites. Prior to joining American Tower, Nate was a Junior Partner in the Corporate Department of Wilmer Cutler Pickering Hale and Dorr (WilmerHale). He holds a J.D. from New York University School of Law and a B.A. in Political Science and Economics from Emory University. “I am thrilled to join the STAAR leadership team at a time of significant opportunity and growth for our vision correction lenses,” said Nate Sisitsky. About STAAR Surgical STAAR, which has been dedicated solely to ophthalmic surgery for over 40 years, designs, develops, manufactures and markets implantable lenses for the eye. These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR’s lens used in refractive surgery is called an Implantable Collamer® Lens or “ICL,” which includes the EVO ICL™ product line. More than 3,000,000 ICLs have been sold to date and STAAR markets these lenses in over 75 countries. To learn more about the ICL go to: EVOICL.com. Headquartered in Lake Forest, CA, the company operates manufacturing and packaging facilities in Aliso Viejo, CA, Monrovia, CA and Nidau, Switzerland. For more information, please visit the Company’s website at . View source version on businesswire.com: Contacts Investors & Media Brian Moore Vice President, Investor Relations and Corporate Development (626) 303-7902, Ext. 3023 bmoore@staar.com Source: STAAR Surgical Company Smart Multimedia Gallery Photo Nancy Sabin, Chief Marketing Officer, STAAR Surgical (Photo: Business Wire) Photo Nathaniel Sisitsky, Senior Vice President, General Counsel and Corporate Secretary, STAAR Surgical (Photo: Business Wire) Logo View this news release and multimedia online at: